<DOC>
	<DOC>NCT00446446</DOC>
	<brief_summary>To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).</brief_summary>
	<brief_title>PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically or cytologically confirmed squamous cell carcinoma of head and neck (SCCHN) of oropharynx, oral cavity, hypopharynx, or larynx with at least 1 measurable lesion using computed tomography (CT) or magnetic resonance imaging (MRI) scan Diagnosis of recurrent disease determined to be incurable by surgery or radiotherapy Karnofsky Performance Status (KPS) score ≥ 60% at screening Men or women age ≥18 years Adequate hematologic, electrolyte and hepatic functions and negative pregnancy test Subject received &gt; 1 chemotherapy regimen for the treatment of metastatic or recurrent disease Concomitant chemotherapy for recurrent disease administered solely for the purpose of radiation sensitization during reirradiation will not be counted towards this chemotherapy regimen Nasopharyngeal carcinoma, salivary gland and primary skin SCCHN, or symptomatic central nervous system (CNS) metastases History of interstitial lung disease, significant cardiovascular disease, or another primary cancer Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic hepatitis B infection Known allergy or hypersensitivity to any component of panitumumab Prior antiepidermal growth factor receptor (EGFr) antibody therapy (eg, panitumumab, cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib) for recurrent or metastatic disease with the following exceptions: Prior EGFr inhibitor therapy is allowed if received as part of prior multimodality treatment (eg, as radiation sensitizer) and completed &gt; 24 weeks prior to randomization Subjects who received no more than one dose of cetuximab and discontinued prior to progression due to documented severe infusion reaction are eligible. Significant thromboembolic event ≤ 8 weeks prior to enrollment Subjects not recovered from all previous acute radiotherapyrelated toxicities History of severe skin disorder that in the opinion of the investigator may interfere with study conduct History of any medical, or psychiatric condition, or laboratory abnormality that may interfere with the interpretation of study results Subject is currently in a clinical trial ≤ 30 days prior to enrollment Subjects requiring use of immunosuppressive agents however corticosteroids are allowed Man or woman of childbearing potential who do not consent to use adequate contraceptive precautions during the course of the study Female subject who is pregnant or breastfeeding Subject requiring major surgery using general/spinal anesthesia ≤ 28 days prior to enrollment, or minor surgery ≤ 14 days prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>